NCT00860340
Completed
Not Applicable
Hemodynamic Effects of Spironolactone in Patients With Heart Failure
University of Toledo Health Science Campus1 site in 1 country18 target enrollmentFebruary 2003
Overview
- Phase
- Not Applicable
- Intervention
- Spironolactone
- Conditions
- Congestive Heart Failure
- Sponsor
- University of Toledo Health Science Campus
- Enrollment
- 18
- Locations
- 1
- Primary Endpoint
- Echocardiogram
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
To determine if the beneficial effect of spironolactone in patients with congestive heart failure is in part due to its intrinsic inotropic action.
Randomized, two group placebo controlled, single blind study.
Investigators
Eligibility Criteria
Inclusion Criteria
- •21 - 80 years
- •Serum creatinine \< 2 mg/dL
- •Serum potassium 2.7 - 4.5 mg/dL measured within past 4 weeks
Exclusion Criteria
- •Less than 21 years
- •Pregnancy
Arms & Interventions
1
Study patient will take 100mg tablet of Spironolactone
Intervention: Spironolactone
Outcomes
Primary Outcomes
Echocardiogram
Time Frame: 3 measurements 15 minutes apart before drug and 15 minutes for 2 hours after drug
Measure of Kidney function and potassium levels
Time Frame: This will be taken before drug, two hours after and the following day
Study Sites (1)
Loading locations...
Similar Trials
Terminated
Phase 3
Spironolactone in the Treatment of Heart FailureNCT04727073Charite University, Berlin, Germany743
Completed
Phase 2
Spironolactone in Adult Congenital Heart DiseaseCongenital Heart DiseaseHeart FailureEndomyocardial FibrosisNCT01069510Oregon Health and Science University40
Completed
Phase 4
Antiarrhythmic Effects of Spironolactone in Patients With ICDsVentricular ArrhythmiasNCT04495712VA Office of Research and Development90
Withdrawn
Phase 4
Spironolactone to Improve Apnea and Cardiovascular Markers in Obstructive Sleep Apnea PatientsObstructive Sleep ApneaNCT04205136University of Michigan
Recruiting
Phase 3
SPIRonolactone In the Treatment of Heart Failure - A double-blind, randomized, placebo-controlled, parallel group, interventional phase III study to evaluate the efficacy and safety of spironolactone compared to placebo on the composite endpoint of recurrent heart failure hospitalizations and cardiovascular death in patients with heart failure with mid- range or preserved ejection fractioHeart failure with preserved or mid-range ejection fractionHFmrEF and HFpEF10019280NL-OMON54576Charité Universitätsmedizin Berlin100